2023
DOI: 10.1016/j.cmi.2022.12.007
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 28 publications
0
1
0
Order By: Relevance
“…Nonetheless increased dosing is not always needed. Among 70 allogeneic hematopoietic stem cell transplant recipients (mean age 47.2 ± 14.4 years), 4 versus 3 doses PCV13 before PPSV23 did not yield a significant difference in the IgG response rate (≥0.20 mg/mL) for 8 measured serotypes at 5 months after the PPSV23 booster (100% vs. 93%) [ 87 ].…”
Section: Future Directionsmentioning
confidence: 99%
“…Nonetheless increased dosing is not always needed. Among 70 allogeneic hematopoietic stem cell transplant recipients (mean age 47.2 ± 14.4 years), 4 versus 3 doses PCV13 before PPSV23 did not yield a significant difference in the IgG response rate (≥0.20 mg/mL) for 8 measured serotypes at 5 months after the PPSV23 booster (100% vs. 93%) [ 87 ].…”
Section: Future Directionsmentioning
confidence: 99%